Related Experiment Video
Updated: Jan 18, 2026

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
Published on: August 1, 2025
Vanishing Bile Duct Syndrome Caused by a Treatment Regimen Including Avacopan for Microscopic Polyangiitis
Mako Hishinuma1, Midori Hasegawa2, Shun Minatoguchi1
1Department of Nephrology, Fujita Health University School of Medicine, Japan.
Abstract:
An 81-year-old man was treated with prednisolone, avacopan, and rituximab for microscopic polyangiitis and sulfamethoxazole/trimethoprim (SMX/TMP) and vonoprazan for prophylaxis. The liver enzyme levels were elevated 42 days after avacopan administration. Avacopan, SMX/TMP, and vonoprazan treatment were discontinued. A liver biopsy revealed vanishing bile duct syndrome. The patient was subsequently treated with ursodeoxycholic acid and glucocorticoid. Although vasculitis remained in remission, the patient ultimately died. Autopsy revealed persistent bile ductopenia and progressive liver cell injury confirmed by cytokeratin 7 positivity, severe cholestasis, and portal fibrosis. Further studies are required to elucidate associated mechanisms and risk factors.
Insights
Avacopan treatment for microscopic polyangiitis led to vanishing bile duct syndrome and liver injury, despite successful vasculitis remission. The patient ultimately died from progressive liver damage.
Area of Science:
- Hepatology
- Immunology
- Nephrology
Background:
- Microscopic polyangiitis is a severe autoimmune vasculitis.
- Avacopan is a novel treatment for ANCA-associated vasculitis.
- Drug-induced liver injury is a significant clinical concern.
Purpose of the Study:
- To report a case of vanishing bile duct syndrome associated with avacopan treatment.
- To investigate the potential hepatotoxicity of avacopan in a patient with microscopic polyangiitis.
- To highlight the challenges in managing drug-induced liver injury in elderly patients.
Main Methods:
- Case report of an 81-year-old male patient.
- Treatment with prednisolone, avacopan, and rituximab for microscopic polyangiitis.
- Monitoring of liver enzymes, liver biopsy, and autopsy findings.
Main Results:
- Elevated liver enzymes were observed 42 days after initiating avacopan.
- Liver biopsy confirmed vanishing bile duct syndrome.
- Autopsy revealed persistent bile ductopenia, liver cell injury, cholestasis, and fibrosis.
Conclusions:
- Avacopan may be associated with vanishing bile duct syndrome and severe liver injury.
- Early recognition and discontinuation of the offending agent are crucial.
- Further research is needed to understand the mechanisms and risk factors for avacopan-induced liver injury.
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Endoscopic Procedures V: ERCP
Patient...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
